India Pharmacopoeia Commission joins WHO network

Published: 10-Dec-2015
Regulatory

India has set up 179 centres to monitor adverse drug reactions across the country


The Indian Pharmacopoeia Commission (IPC) is set to become the first World Health Organisation (WHO) Collaborating Centre for the safety of medicines and vaccines in the south and south-east Asia region. These bodies work with the WHO to develop and implement policy.

The move has been welcomed by Indian health and Welfare Minister Shri J P Nadda, who stressed the need to improve pharmacovigilance in the region as 'an effective instrument for understanding and prevention of adverse effects or any other drug related problems'.

He noted that India has set up 179 centres to monitor adverse drug reactions across the country.

  • Companies:
  • World Health Organization
See more

You may also like

Personal Protection

Containment: key to tackling coronavirus outbreak

Read more
China and WHO authorities agreed that further studies on the severity and transmissibility of the virus are needed and immediate communication of any findings is crucial

Trending Articles

  1. Scleroderma treatment by Certa Therapeutics granted US FDA fast track FT011 is a novel, first-in-class oral therapy for the treatment of chronic fibrosis in multiple organs
  2. 4SC AG receives Paediatric Investigation Plan waiver for resminostat from the UK MHRA The waiver allows the company to avoid investigating the CTCL drug in a paediatric population, as it's considered unnecessary or inappropriate for use by this patient group
  3. The key role of IVDs in healthcare: challenges to commercialisation and access In simple terms, in vitro diagnostic (IVD) tests are done on samples such as blood or tissue that have been taken from the human body. IVDs can detect diseases, conditions and infections, provide patients with a better understanding of their ailment and how it might be managed and changed with treatment
  4. How to proactively address EU HTAR implementation challenges before 2025 Data landscape challenges within the European Union (EU) have historically been driven by the different laws, processes and regulatory standards of its 27 member states (MS). As a result, drug therapeutics and health technology developers have faced the challenge of duplication of assessment efforts
  5. Post-Brexit border paperwork and inspections postponed for life sciences sector The six month extension will allow life science companies to the make necessary alterations to their supply chains to accommodate for the novel post-Brexit border paperwork

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

You may also like

Personal Protection

Containment: key to tackling coronavirus outbreak

China and WHO authorities agreed that further studies on the severity and transmissibility of the virus are needed and immediate communication of any findings is crucial
Regulatory

WHO proposes central registry on human genome editing research

On the heels of the Chinese CRISPR scandal, stakeholders in the genome editing industry will be consulted to create standards for future research
Regulatory

Annex 1 harmonisation moves a step closer

Revision to Annex 1 on the manufacturing of sterile medicinal products of the PIC/S – EU GMP Guide goes out for joint stakeholder consultation
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

EU considers endocrine disrupter controls

It has long been known that pharmaceutical residues can become hormone-affecting ‘endocrine disrupters’ when released into the environment and future controls are likely – but how will the legislators tackle the issue? Manufacturing Chemist reports
Regulatory

European Commission, EMA and WHO step up co-operation to protect global public health

New working arrangement will allow timely sharing of non-public information
Regulatory

Vietnamese national regulatory authority meets international standards for vaccine regulation

The World Health Organisation has formally certified that Vietnam has a fully equipped national regulatory system that ensures the safety and efficacy of vaccines produced and used in the country
Regulatory

Chinese medicine body joins list of WHO observers

Will give traditional Chinese medicine (TCM) a voice in international health affairs
Subscribe now